Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
VIH.BK
Strong BuyFull HouseSrivichaivejvivat Public Company Limited · Healthcare · Thailand · $160M · Avg Vol: $65K/d
COMPANY DESCRIPTION
Srivichaivejvivat Public Company Limited, together with its subsidiaries, engages in the hospital business in Thailand.
FINANCIAL SUMMARY (THB)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 3.6B | 2.7B | 2.8B | 3.1B | -5.7% | 3.2B |
| EPS (THB) | 1.22 | 0.50 | 0.53 | 0.72 | -16.2% | 0.73 |
| Shares | 570.7M | 570.7M | 608.7M | 608.4M | +6.6% | 626.8M |
| Debt | 186.4M | 125.5M | 66.3M | 67.5M | -28.7% | 65.6M |
| Equity | 3.0B | 3.0B | 3.5B | 3.9B | 8.9% | — |
| Op CF | 940.1M | 383.6M | 501.3M | 513.7M | -18.2% | 536.9M |
| Inv CF | -639.7M | -281.4M | -393.5M | -657.6M | — | — |
| Fin CF | -422.4M | -342.8M | 111.7M | -90.8M | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of VIH.BK are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| VIH.BK | Srivichaivejvivat Public Company Limited(you) | $160M | 98 | Strong Buy |
| RJH.BK | Rajthanee Hospital Public Company Limited | $135M | 95 | Strong Buy |
| EKH.BK | Ekachai Medical Care Public Company Limited | $127M | 88 | Strong Buy |
| TNH.BK | Thai Nakarin Hospital Public Company Limited | $156M | 79 | Buy |
| NTV.BK | Nonthavej Hospital Public Company Limited | $93M | 89 | Strong Buy |
| RPH.BK | Ratchaphruek Hospital Public Company Limited | $79M | 89 | Strong Buy |
| CHG.BK | Chularat Hospital Public Company Limited | $519M | 95 | Strong Buy |
| SKR.BK | Sikarin Public Company Limited | $483M | 92 | Strong Buy |
| CMR.BK | Chiang Mai Ram Medical Business Public Company Limited | $161M | 67 | Buy |
| PR9.BK | Praram 9 Hospital Public Company Limited | $464M | 88 | Strong Buy |
Peer medians: ROE 12.2% · P/E 15.4x · Gross margin 27.9%